Drug Combination Acts Against Aggressive Chronic Lymphocytic Leukemia

A two-prong approach combining ibrutinib and rituximab (Rituxin(r)) to treat aggressive chronic lymphocytic leukemia (CLL) produced profound responses with minor side effects in a Phase 2 clinical trial at the University of Texas MD Anderson Cancer Center.

Read the whole article on Newswise - Scinews

More from Newswise - Scinews